Abstract
Purpose
Hypopituitary patients have a reduced life expectancy owing to cardiovascular events. We investigated the prevalence of metabolic syndrome in hypopituitary patients for a follow-up period of at least 1 year in comparison with an age- and sex-matched nationwide control group.
Methods
A total of 515 patients with hypopituitarism who visited Seoul National University Hospital between January 2000 and December 2010 were included. Data for an age- and sex-matched control group were obtained from the Korean National Health and Nutrition Examination Surveys (KNHANES) (n = 1545). Metabolic syndrome was defined according to the modified National Cholesterol Education Program (NCEP-ATPIII).
Results
The prevalence of metabolic syndrome did not differ significantly between the hypopituitary and control groups for men (34.9 versus 30.3 %), but the risk of metabolic syndrome was higher in hypopituitary women than in controls (39.8 versus 28.5 %). In both sexes, the risks of central obesity and dyslipidemia were higher in the hypopituitary group than in the control group. Men had lower risks of hypertension and hyperglycemia in the hypopituitary group, which attenuated the risk of metabolic syndrome. Age greater than 40 years and obesity (BMI ≥25 kg/m2) contributed to a higher risk of metabolic syndrome.
Conclusions
The metabolic syndrome prevalence was higher in the hypopituitry group than in the control group in Korean women, and this was attributed to an increased risk of central obesity and dyslipidemia. Accordingly, early intervention to reduce metabolic syndrome needed in hypopituitary patients, i.e. women.
Similar content being viewed by others
References
Regal M, Paramo C, Sierra SM, Garcia-Mayor RV (2001) Prevalence and incidence of hypopituitarism in an adult Caucasian population in northwestern Spain. Clin Endocrinol (Oxf) 55(6):735–740
Park H, Kim S (1996) KIm, S., JS., C., Kim, H., Shin, C., Park, K., Kim, S., Cho, B., Lee, H., Koh, C.: A clinical study on hypopituitarism. Endocrinology and Metabolism 11(3):268–276
Sherlock M, Ayuk J, Tomlinson JW, Toogood AA, Aragon-Alonso A, Sheppard MC, Bates AS, Stewart PM (2010) Mortality in patients with pituitary disease. Endocr Rev 31(3):301–342. doi:10.1210/er.2009-0033
Nielsen EH, Lindholm J, Laurberg P (2007) Excess mortality in women with pituitary disease: a meta-analysis. Clin Endocrinol (Oxf) 67(5):693–697. doi:10.1111/j.1365-2265.2007.02947.x
Rosen T, Bengtsson B-Å (1990) Premature mortality due to cardiovascular disease in hypopituitarism. The Lancet 336(8710):285–288
Rosen T, Bosaeus I, Tolli J, Lindstedt G, Bengtsson BA (1993) Increased body fat mass and decreased extracellular fluid volume in adults with growth hormone deficiency. Clin Endocrinol (Oxf) 38(1):63–71
Binnerts A, Deurenberg P, Swart GR, Wilson JH, Lamberts SW (1992) Body composition in growth hormone-deficient adults. Am J Clin Nutr 55(5):918–923
Salomon F, Cuneo RC, Hesp R, Sonksen PH (1989) The effects of treatment with recombinant human growth hormone on body composition and metabolism in adults with growth hormone deficiency. N Engl J Med 321(26):1797–1803. doi:10.1056/nejm198912283212605
Beshyah SA, Freemantle C, Thomas E, Rutherford O, Page B, Murphy M, Johnston DG (1995) Abnormal body composition and reduced bone mass in growth hormone deficient hypopituitary adults. Clin Endocrinol (Oxf) 42(2):179–189
Wuster C, Slenczka E, Ziegler R (1991) Increased prevalence of osteoporosis and arteriosclerosis in conventionally substituted anterior pituitary insufficiency: need for additional growth hormone substitution? Klin Wochenschr 69(16):769–773
Cuneo RC, Salomon F, Watts GF, Hesp R, Sonksen PH (1993) Growth hormone treatment improves serum lipids and lipoproteins in adults with growth hormone deficiency. Metabolism 42(12):1519–1523
de Boer H, Blok GJ, Voerman HJ, Phillips M, Schouten JA (1994) Serum lipid levels in growth hormone-deficient men. Metabolism 43(2):199–203
Garrow J (1991) Importance of obesity. BMJ 303(6804):704–706
Abs R, Mattsson AF, Thunander M, Verhelst J, Goth MI, Wilton P, Koltowska-Haggstrom M, Luger A (2013) Prevalence of diabetes mellitus in 6050 hypopituitary patients with adult-onset GH deficiency before GH replacement: a KIMS analysis. Eur J Endocrinol 168(3):297–305. doi:10.1530/EJE-12-0807
Bougneres PF, Artavia-Loria E, Ferre P, Chaussain JL, Job JC (1985) Effects of hypopituitarism and growth hormone replacement therapy on the production and utilization of glucose in childhood. J Clin Endocrinol Metab 61(6):1152–1157. doi:10.1210/jcem-61-6-1152
Longobardi S, Cuocolo A, Merola B, Di Rella F, Colao A, Nicolai E, Cardei S, Salvatore M, Lombardi G (1998) Left ventricular function in young adults with childhood and adulthood onset growth hormone deficiency. Clin Endocrinol (Oxf) 48(2):137–143
Kaji H, Iida K, Takahashi Y, Okimura Y, Chihara K (2007) Hormone replacement therapy and vascular risk disorders in adult hypopituitarism. Endocr J 54(2):239–245
Attanasio AF, Mo D, Erfurth EM, Tan M, Ho KY, Kleinberg D, Zimmermann AG, Chanson P (2010) Prevalence of metabolic syndrome in adult hypopituitary growth hormone (GH)-deficient patients before and after GH replacement. J Clin Endocrinol Metab 95(1):74–81. doi:10.1210/jc.2009-1326
Verhelst J, Mattsson AF, Luger A, Thunander M, Goth MI, Koltowska-Haggstrom M, Abs R (2011) Prevalence and characteristics of the metabolic syndrome in 2479 hypopituitary patients with adult-onset GH deficiency before GH replacement: a KIMS analysis. Eur J Endocrinol 165(6):881–889. doi:10.1530/EJE-11-0599
Rosenbaum PR, Rubin DB (1983) The central role of the propensity score in observational studies for causal effects. Biometrika 70(1):41–55
Joffe MM, Rosenbaum PR (1999) Invited commentary: propensity scores. Am J Epidemiol 150(4):327–333
Baser O (2006) Too much ado about propensity score models? Comparing methods of propensity score matching. Value in Health 9(6):377–385
Ford ES, Giles WH, Mokdad AH (2004) Increasing prevalence of the metabolic syndrome among u.s. Adults. Diabetes Care 27(10):2444–2449
Alberti KG, Zimmet P, Shaw J (2005) Group, I.D.F.E.T.F.C.: the metabolic syndrome–a new worldwide definition. Lancet 366(9491):1059–1062. doi:10.1016/S0140-6736(05)67402-8
van der Klaauw AA, Biermasz NR, Feskens EJ, Bos MB, Smit JW, Roelfsema F, Corssmit EP, Pijl H, Romijn JA, Pereira AM (2007) The prevalence of the metabolic syndrome is increased in patients with GH deficiency, irrespective of long-term substitution with recombinant human GH. Eur J Endocrinol 156(4):455–462. doi:10.1530/EJE-06-0699
Abs R, Feldt-Rasmussen U, Mattsson AF, Monson JP, Bengtsson BA, Goth MI, Wilton P, Koltowska-Haggstrom M (2006) Determinants of cardiovascular risk in 2589 hypopituitary GH-deficient adults - a KIMS database analysis. Eur J Endocrinol 155(1):79–90. doi:10.1530/eje.1.02179
Davidson MB (1987) Effect of growth hormone on carbohydrate and lipid metabolism. Endocr Rev 8(2):115–131. doi:10.1210/edrv-8-2-115
Johansson JO, Fowelin J, Landin K, Lager I, Bengtsson BA (1995) Growth hormone-deficient adults are insulin-resistant. Metabolism 44(9):1126–1129. doi:10.1016/0026-0495(95)90004-7
Bulow B, Hagmar L, Eskilsson J, Erfurth EM (2000) Hypopituitary females have a high incidence of cardiovascular morbidity and an increased prevalence of cardiovascular risk factors. J Clin Endocrinol Metab 85(2):574–584. doi:10.1210/jcem.85.2.6346
Sesmilo G, Miller KK, Hayden D, Klibanski A (2001) Inflammatory cardiovascular risk markers in women with hypopituitarism. J Clin Endocrinol Metab 86(12):5774–5781. doi:10.1210/jcem.86.12.8087
Carr MC (2003) The emergence of the metabolic syndrome with menopause. J Clin Endocrinol Metab 88(6):2404–2411. doi:10.1210/jc.2003-030242
Acknowledgments
We thank all colleagues who contributed to the study.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
The study was conducted in accordance with the Declaration of Helsinki and complies with the current laws of the countries in which it was performed. An independent ethics committee or institutional review board for each study site approved the study protocol.
Conflict of interest
Nothing to declare.
Informed consent
An informed consent was waivered due to a retrospective study.
Rights and permissions
About this article
Cite this article
Khang, A.R., Ku, E.J., Kim, Y.A. et al. Sex differences in the prevalence of metabolic syndrome and its components in hypopituitary patients: comparison with an age- and sex-matched nationwide control group. Pituitary 19, 573–581 (2016). https://doi.org/10.1007/s11102-016-0747-9
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11102-016-0747-9